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Abstract
Background: Epstein-Barr virus (EBV) and human cytomegalovirus (CMV) infections are environmental risk factors
affecting the outcome of cancer due to an impairment in the cell-mediated immunity. Therefore, this study aimed
to detect the frequency of EBV and CMV DNA and their association with clinical characteristics and outcome of
pediatric leukemic patients.
Methods: Samples of 50 immunocompromised pediatric leukemic patients and 30 apparently healthy children were
subjected to the amplification of EBV DNA by one version of PCR targeting the Bam H1 W region of the genomic region
of EBV, and the amplification of CMV DNA by targeting the CMV UL97 genomic region by a second round PCR. All
investigations were performed on WBCs and sera. Results were correlated with the clinical and laboratory characteristics
of the disease, and with overall survival.
Results: EBV and CMV DNA were detected in 20 and 54% of leukemic patients, respectively. Nine out of ten patients with
EBV DNA (90%) were positive for CMV DNA in their sera. The presence of EBV DNA or CMV DNA was associated with
neutropenia and a low total leukocyte count (TLC) (p = 0.02, 0.03, respectively). The presence of severe CMV disease,
longer duration of febrile neutropenia, neutropenia, lymphopenia, thrombocytopenia and the presence of EBV DNA in
patients’ sera were significantly associated with worse overall survival.
Conclusion: The detection of CMV disease and EBV DNA is relatively common in leukemic children and is significantly
associated with a decline in the overall survival.
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Background
It is now known that Cytomegalovirus (CMV) and
Epstein-Barr virus (EBV) infect about 90% of the popu-
lation globally, and that infection continues in a latent
phase [1]. Viral infections, particularly caused by herpes-
viruses, were documented as important cause of morbid-
ity and mortality in immunocompromised patients with
a hematological malignancy [2, 3]. Immunosuppression
conditions –like those faced in cancer patients- can lead
to reactivation years later [1, 4]. Recent evidence shows
that the activity of viral proteins interferes with cellular
pathways controlling growth and survival, which may
lead to crucial cellular transformation [5]. EBV was first
identified in cultured Burkitt’s lymphoma cells 40 years
ago [6], and coinfection with EBV has been linked with
Hodgkin’s disease, large cell lymphoma, and chronic
lymphocytic leukemia in adults [7, 8]. Therefore, the
detection and quantification of these viruses help in clin-
ical management; and prompt early treatment in order
to prevent further progression in disease course [9, 10].
CMV and EBV are the most common infections in
pediatric leukemic patients as a result of leukemia-
associated immunosuppression status [11, 12]. There are
a few reports about the role of EBV and CMV in
pediatric leukemic patients. A higher exposure to herpes
simplex virus types 1 and 2 (HSV-1 and 2) among acute
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lymphoblastic leukemia (ALL) children in Egypt has
been previously reported [2]. Moreover, Lehtinen and
colleagues reported a possible association between
maternal EBV infection and childhood ALL [13].
Direct detection for herpesvirus infections in immuno-
compromised patients allows simplifying preemptive
therapy through early detection of EBV replication and
is considered a high positive predictive value for the
related infections [14]. The current study aimed, there-
fore, to detect the frequency of EBV and CMV DNA and
their association with the clinical characteristics and the
outcome of pediatric leukemic patients.
Methods
Patients
This prospective study included 50 pediatric patients
with leukemia diagnosed and treated at the pediatric on-
cology department, National Cancer Institute (NCI),
Cairo University between January 2013 and December
2014. Thirty apparently healthy normal individuals with
comparable age and sex were included as a control
group. The Institutional Review board (IRB) of the NCI
approved the protocol (IRP NO. IRP00004025).
Informed consent was obtained from all participants
enrolled in the study. The inclusion criteria were chil-
dren till 18 years old, both sexes, suffering from acute
lymphocytic leukemia (ALL) or acute myeloid leukemia
(AML). All patients were subjected to detailed history,
physical examination, as well as routine clinical and
laboratory investigations. As for clinical assessment, the
patients were checked for fever, organomegaly, mucosi-
tis, lymphadenopathy, chest infection and duration of
febrile neutropenia. Main laboratory tests included;
complete blood count, lactate dehydrogenase level
(LDH), erythrocyte sedimentation rate (ESR), cerebro-
spinal fluid examination (CSF), bone marrow aspiration
(BMA) and liver and renal function tests. Echocardio-
graphic examination, immunophenotyping, karyotyping
and abdominal ultrasound were also performed. Accord-
ingly; diagnosis, disease extent, risk stratification [15],
and comorbidities were determined, and correlated with
the patients’ treatment schedule. The patients were
followed up during the course of treatment for at least
18 months [16].
Response and survival
Assessment of response of acute leukemia was done
after induction treatment using WHO criteria. Scoring
of CMV was calculated according to Plotkin scoring sys-
tem [17] (Table 1). Total score of seven or more was
considered severe CMV infection. Overall survival was
calculated from the date of diagnosis till the date of
death or last follow-up.
Specimen collection
Five ml of whole blood specimen was obtained from each
patient and control. Serum and leukocyte samples were
extracted according to Vander Bij et al.[18] and our previ-
ously published protocols [19, 20], and stored in aliquots
of 100 μl saline at −20 °C until being processed for nucleic
acid extraction.
Nucleic acid extraction
Viral DNA was extracted using QIAamp viral RNA
extraction kit (Qiagen, Valencia, USA). The extraction
was done according to the manufacturer’s instructions.
The amount of viral DNA was measured by spectropho-
tometry using a Nano-Drop 2000 spectrophotometer
(Thermo Scientific/US, Canada) and 100 ng of DNA
template was used in the PCR assays. DNA extracts were
placed on ice and used immediately for PCR, then stored
at −80 °C until further subsequence analysis.
Molecular detection
1. Molecular detection of EBV and CMV DNA: All
samples were subjected to one version PCR assay
targeting nucleotide position from 32104 to
32256 bp of BamH1 W genomic region of EBV
(Accession AB850660) and nucleotide position from
2692 to 2933 bp of UL 97 genomic region of CMV
(Accession FJ616285.1). The amplification was
conducted in a final volume of 25 μl of AmpliTaq
PCR master mix (Biosystems, Barcelona, Spain)
containing 0.2 μM of outer primers using the
thermal cycler (Perkin-Elmer Cetus), according to
previously published protocols [21, 22]. Nucleic
acids of EBV VR-1492 (ATCC-USA) and CMV
VR-538 (ATCC-USA) were extracted using the same
extraction procedure for the samples. EBV and
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CMV-positive and negative (water) controls were
run in each PCR assay.
2. Detection of amplified product by agarose gel
electrophoresis: 17 μl of the PCR product was
subjected to electrophoresis on a 2% agarose gel
(Sigma) in Tris-acetate buffer (TAE 1X) pH 8.2,
stained with 0.5 μg/ml ethidium bromide and
examined under UV transillumination and
photographed. The product sizes were estimated by
comparing with 100 bp DNA ladder (Gendirex,
Taiwan). The amplified fragments were 153 bp for
EBV [21] and 240 bp for CMV [22].
3. Sensitivity of qualitative PCR for detection of
EBV and CMV DNA in clinical specimens: Serial
dilutions were prepared from CMV and
EBV-positive controls and PCR assays were
performed according to the previously published
protocols [21, 22].
4. Specificity of qualitative PCR for detection of
EBV and CMV DNA in clinical specimens: It was
performed by testing samples positive for HSV-1
and 2, herpesvirus 6, Varicella Zoster Virus,
adenovirus and CMV or EBV according to the
tested virus. Then, the PCR assay was performed as
mentioned before.
Statistical analysis
Statistical analysis was done using IBM© SPSS© Statistics
version 22 (IBM© Corp., Armonk, NY, USA). Numerical
data were expressed as a mean and standard deviation or
median and range as appropriate. Qualitative data were
expressed as frequency and percentage. Chi-square test or
Fisher’s exact test was used to examine the relation between
qualitative variables. Survival analysis was done using
Kaplan-Meier method and comparison between two sur-
vival curves was done using log-rank test. All tests were
two-tailed. A p-value < 0.05 was considered significant.
Results
The median age of the 50 pediatric leukemic patients
was 7 years (range: 9.5 months–18 years) while that of
the 30 healthy controls was 11 years (range: 4–18
years). Male to female ratio was 1.08:1 in patients, and
2:1 in controls. The two groups were comparable in age
(p = 0.267) and sex (p = 0.199). The demographic,
clinical, and laboratory characteristics of patients are
summarized in Table 2. All patients had fever and signs
of chest infections, and 70% of them had organomegaly.
Laboratory (hematological and biochemical) data of the
leukemia group are illustrated in Table 3. The most
observed abnormal biochemical parameters are LDH
and SGOT levels observed in about 94 and 30% of pa-
tients, respectively.
Disease characteristics and outcome of patients
Ten patients had AML and 40 had ALL; 10 of them
were T-ALL. Eighty-eight percent of patients re-
ceived consolidation treatment, 6% were under main-
tenance therapy and 6% were under salvage therapy.
At the end of the study, the mortality rate was 32/
50 (64%).
Presence of EBV and CMV DNA in studied groups
The distribution of EBV and CMV DNA in serum were
significantly different between leukemic and control
groups (p = 0.048). Likewise, the distribution of both
viruses in leukocytes was significantly different between
leukemic and control groups (p < 0.001) (Table 4).
EBV and/or CMV frequencies were higher in sera
of leukemic patients (28/50, 56%). EBV and CMV co--
infection was detected in nine leukemia patients
(18%) and none of the controls. The number of pa-
tients with co-infection was too small to be associated
statistically with the development of severe CMV dis-
ease (n = 9). There was no significant association of
any of the clinical and laboratory parameters with the
active co-infection.
Sensitivity and specificity of qualitative PCR assay for
detection of EBV and CMV DNA
Such assays were found to be highly specific for EBV
BamH1 W region and CMV UL97 as none of the other
viruses tested was amplified. The sensitivity level of
qualitative PCR assay was approximately 100 copies/μl
for both viruses, which represents the lowest standard
dilution that could be detected.
Table 2 Demographics and clinical characteristics of pediatric
leukemia patients (n = 50)
Characteristics N (%)










Chest infection 50 (100%)
Duration of Febrile neutropenia, median
(range)
26.5 days (9–60)
Severe CMV disease 32 (64%)
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Table 3 Some laboratory parameters of leukemia patients
Laboratory parameter Leukemia group N = 50




1- Liver function test (LFT):
Serum glutamic-pyruvic transaminase (SGPT) 0-41 IU/L 7 (14) 20.1 (1–317)
High risk: Level more than 41 IU/L
Serum glutamic oxaloacetic transaminase (SGOT) 0-32 IU/L 15 (30) 23.50 (9–273)
High risk: Level more than 32 IU/L
Total Bilirubin 0-1.2 mg/dl 1 (2) 0.45 (0.1–1.7)
High risk: Level more than 1.2 mg/dl
2- Kidney function test (KFT):
Creatinine 0.8-1.3 mg/dl 3 (6) 0.4 (0.1–2.2)
High risk: Level more than 1.3 mg/dl
Uric Acid 3.4-7 mg/dl 3 (6) 3.4 (1–24)
High risk: Level more than >7 mg/dl
Lactate dehydrogenase (LDH) 125-220 IU/L 47 (94) 907 (11–9635)
High risk: Level more than 220 IU/L
3- Complete blood count (CBC):
Hemoglobin concentration (Hb) 11.5-15.5 g/dl 40 (80) 7.4 (3.9–14.1)
High risk: Level less than <11.5 g/dl
Total leukocyte count (TLC) 4500-11000 cell/cmm 11 (22) 11950 (1080–731500)
High risk: Leucopenia <4500cell/cmm
Platelet count (Plt) 150-440 × 109/l 40 (80) 39.5 (7–694)
High risk: Thrombocytopenia <150 × 109/l
Absolute neutrophile count (ANC) 2-7 × 109/l 42(84) 0.13 (0–3.83)
High risk: Neutropenia <2 × 109/l
Absolute Monocyte count (AMC) 0.2-1.2 × 109/l 29 (58) 0.11 (0–9.66)
High risk: Monocytopenia <0.2 × 109/l
Absolute Lymphocyte count (ALC) 1-3.5 × 109/l 23 (46) 1.2 (0–143.3)
High risk: Lymphopenia <1 × 109/l
IU/L International unit per liter, mg/dl milligram per deciliter, g/dl gram per deciliter
Table 4 Detection of herpesviruses by PCR in both sera and WBCs of the studied groups expressed as number and percentage
Group EBV DNA CMV DNA Both EBV/CMV DNA Negative for herpesviruses
Serum
Leukemia (n = 50) 1 (2.0%) 18 (36.0%) 9 (18.0%) 22 (44.0%)
Control (n = 30) 0 (0.0%) 14 (46.7%) 0 (0.0%) 16 (53.3%)
p Value =0.048
WBCs
Leukemia (n = 50) 14 (28%) 10 (20%) 9 (18%) 17 (34%)
Control (n = 30) 0 (0%) 12 (40%) 0 (0.0%) 18 (60%)
p Value <0.001
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Relation between presence of EBV and/or CMV and
demographic, clinical and biochemical parameters in
leukemia patients
Mucositis was more common in leukemic patients nega-
tive for herpesviruses in serum than in positive patients,
with borderline statistical significance (p = 0.07). Neutro-
penia (ANC <0.13 × 109/l) was more observed in
patients with EBV and/ or CMV DNA in serum than in
those with EBV/CMV co-infection and negative patients,
with borderline significance (p = 0.07) (Table 5). No sig-
nificant association of presence of herpesvirus DNA with
other high risk clinical parameters; lymphopenia (<1.2 ×
109/l), thrombocytopenia (Plt < 39.5 × 109/l), and low Hb
level (<7.4 g/dl) (Tables 5 and 6).
Table 5 Relation between demographic, clinical, and biochemical findings and CMV and/or EBV as detected in serum by qualitative









≤6 years (n = 23) 7 (30.4%) 5 (21.7%) 11 (47.8%)
>6 years (n = 27) 12 (44.4%) 4 (14.8%) 11 (40.7%)
Sex 0.53
Male (n = 26) 11 (42.3%) 3 (11.5%) 12 (46.2%)
Female (n = 24) 8 (33.3%) 6 (25%) 10 (41.7%)
Mucositis 0.07
Yes (n = 22) 7 (31.8%) 7 (31.8%) 8 (36.4%)
No (n = 28) 12 (42.9%) 2 (7.1%) 14 (50.0%)
Organomegaly 0.72
Yes (n = 35) 14 (40.0%) 7 (20.0%) 14 (40.0%)
No (n = 15) 5 (33.3%) 2 (13.3%) 8 (53.4%)
DFN (days) 0.75
<26.5 (n = 25) 8 (32%) 5 (20%) 12 (48%)
>26.5 (n = 25) 11 (44%) 4 (16%) 10 (40%)
ANC (×109/L) 0.07
<0.13 (n = 25) 13 (52%) 2 (8%) 10 (40%)
≥0.13 (n = 25) 6 (24%) 7 (28%) 12 (48%)
Plt count (×109/L) 0.27
<39.5 (n = 25) 7 (28%) 4 (16%) 14 (56%)
≥39.5 (n = 25) 12 (48%) 5 (20%) 8 (32%)
Hb (gm/dL) 0.65
<7.4 (n = 25) 10 (40%) 3 (12%) 12 (48%)
≥7.4 (n = 25) 9 (36%) 6 (24%) 10 (40%)
AMC(×109/L) 0.43
<0.11 (n = 25) 9 (36%) 3 (12%) 13 (52%)
≥0.11 (n = 25) 10 (40%) 6 (24%) 9 (36%)
TLC(cell/mm3) 0.57
<11950 (n = 25) 11 (44%) 5 (20%) 9 (36%)
≥11950 (n = 25) 8 (32%) 4 (16%) 13 (52%)
ALC(×109/L) 0.93
<1.2 (n = 24) 10 (41.7%) 4 (16.7%) 10 (41.7%)
≥1.2 (n = 26) 9 (34.6%) 5 (19.2%) 12 (46.2%)
Numerical factors were divided according to their median values
DFN Duration of febrile neutropenia, HG hemoglobin, TLC Total leukocytic count, Plt platelets, ANC Absolute neutrophilic count, AMC Absolute monocytic count,
ALC Absolute lymphocytic count
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Relation between presence of EBV and/or CMV and
overall survival in leukemia patients
The median follow-up period of leukemia patients was
23.4 months (range: 18–28.7 months). The cumulative
overall survival at 24 months was 47.4%. The Survival of
pediatric leukemia patients was significantly worse in asso-
ciation with severe CMV disease (p = 0.002), longer dur-
ation of febrile neutropenia (p = 0.024), thrombocytopenia
(p = 0.024), presence of active EBV infection (p = 0.038),
lymphopenia (p = 0.042), and neutropenia (p = 0.044). EBV
and CMV co-infection had borderline effect on the overall
survival of patients (p = 0.079) (Table 7, Figs. 1, 2, 3, 4, 5
and 6).
Discussion
In recent years, a causal relationship between EBV and a
variety of childhood leukemia has been demonstrated.
Our previous report showed the synergistic effect of
Table 6 Relation between demographic, clinical, and biochemical findings and CMV and/or EBV as detected in leukocytes by











≤6 years (n = 23) 8 (34.8%) 6 (26.1%) 3 (13%) 6 (26.1%)
>6 years (n = 27) 6 (22.2%) 4 (14.8%) 6 (22.2%) 11 (40.7%)
Sex 0.94
Male (n = 26) 7 (26.9%) 6 (23.1%) 5 (19.2%) 8 (30.8%)
Female (n = 24) 7 (29.2%) 4 (16.7%) 4 (16.7%) 9 (37.5%)
Mucositis 0.60
Yes (n = 22) 4 (18.2%) 5 (22.7%) 5 (22.7%) 8 (36.4%)
No (n = 28) 10 (35.7%) 5 (17.9%) 4 (14.3%) 9 (32.1%)
Organomegaly 0.61
Yes (n = 35) 11 (31.4%) 8 (22.9%) 6 (17.1%) 10 (28.6%)
No (n = 15) 3 (20.0%)) 2 (13.3%) 3 (20.0%) 7 (46.7%)
DFN (days) 0.79
<26.5 (n = 25) 7 (28.0%) 4 (16.0%) 4 (16.0%) 10 (40.0%)
>26.5 (n = 25) 7 (28.0%) 6 (24.0%) 5 (20.0%) 7 (28.0%)
ANC(×109/L) 0.84
<0.13 (n = 25) 8 (32%) 4 (16%) 5 (20%) 8 (32%)
≥0.13 (n = 25) 6 (24%) 6 (24%) 4 (16%) 9 (36%)
Plt count(×109/L) 0.90
<39.5 (n = 25) 7 (28.0%) 6 (24.0%) 4 (16.0%) 8 (32.0%)
≥39.5 (n = 25) 7 (28.0%) 4 (16.0%) 5 (20.0%) 9 (36.0%)
Hb(gm/dL) 0.12
<7.4 (n = 25) 8 (32%) 5 (20%) 7 (28%) 5 (20%)
≥7.4 (n = 25) 6 (24.0%) 5 (20.0%) 2 (8.0%) 12 (48.0%)
AMC(×109/L) 0.67
<0.11 (n = 25) 8 (32%) 6 (24%) 3 (12%) 8 (32%)
≥0.11 (n = 25) 6 (24%) 4 (16%) 6 (24%) 9 (36%)
TLC(cell/mm3) 0.59
<11950 (n = 25) 6 (24%) 6 (24%) 6 (24%) 7 (28%)
≥11950 (n = 25) 8 (32%) 4 (16%) 3 (12%) 10 (40%)
ALC(×109/L) 0.79
<1.2 (n = 24) 8 (33.3%) 4 (16.7%) 5 (20.8%) 7 (29.2%)
≥1.2 (n = 26) 6 (23.1%) 6 (23.1%) 4 (15.4%) 10 (38.5%)
DFN Duration of febrile neutropenia, HG hemoglobin, TLC Total leukocytic count, Plt platelets, ANC Absolute neutrophilic count, AMC Absolute monocytic count,
ALC Absolute lymphocytic count
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Table 7 Overall survival of the leukemic patients and its relation to different prognostic factors
Cumulative survival at 24 month (%) Median Survival (months) p value
Diagnosis




>26.5 35.4 16.5 0.024
ANC (×109/L)
<0.13 15.6 16.5
≥0.13 56.6 32.3 0.044
Plt count (×109/L)
<39.5 14.7 16.5
≥39.5 68.3 44.3 0.024
ALC (×109/L)
<1.2 12.2 16.5 0.042
≥1.2 62.6 32.3
CMV score
<7 (n = 8) 80.0 15.1 0.002
≥7 (n = 20) 26.1% 23.5
EBV PCR Serum
Positive (n = 9) 68.6 91.6
Negative (n = 29) 33.7 21.5 0.038
CMV&EBV in serum
Both negative(n = 15) 30.8 21.6 0.079
CMV alone/EBV alone(n = 15) 25.9 32.3
Both positive(n = 8) 62.5 91.6
Numerical factors were divided according to their median values
DFN Duration of febrile neutropenia, Plt platelets, ANC Absolute neutrophilic count, ALC Absolute lymphocytic count
Fig. 1 Relation of overall survival (OS) with duration of febrile neutropenia (DFN) in pediatric ALL patients
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HHV6 on CMV-associated infection resulting in severe
outcome among pediatric lymphoma patients [19]. This
encouraged us to investigate the frequency of EBV and
CMV infections and their impact when existed together
on the clinical course of leukemia disease. EBV DNA
whether alone or with CMV was detected in the sera of
10/50 (20%) of our leukemia patients but not in control
subjects. There are few reports in literature on the role
of EBV in childhood leukemia. Sehgal and coworkers
have detected EBV DNA in 8/25 (32%) of pediatric ALL
patients by PCR amplification of BamH1-W EBV nu-
clear antigen (EBNA) promoter [23]. They have also ob-
served the presence of EBV LMP1 gene transcripts in
29/80 (36.3%) Sudanese patients with leukemia disease,
but not in healthy controls (p = 0.0001) [24]. Moreover,
It has been reported that the presence of EBV DNA in
22.8% of pediatric ALL patients, but not in the control
group [25].
In the present study, CMV DNA alone or combined
with EBV DNA was detected in 27/50 (54%) of the sera
of leukemic patients. Debaugnies and coworkers have
detected EBV and CMV DNA in 19 and 27% in the
whole blood samples from immunocompromised adult
and pediatric patients respectively [26].
Regarding the detection of both herpesviruses in
WBCs in the present study, EBV DNA was found in
23/50 (46%) while CMV DNA in 19/50 (38%) among
leukemic patients. This was higher than that reported
by Lu and coworkers who have detected EBV DNA
in 8/35 (22.86%) of pediatric leukemia patients using
Fig. 2 Relation of overall survival with absolute neutrophilic count (ANC) in pediatric ALL patients
Fig. 3 Relation of overall survival with platelet count in pediatric ALL patients
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fluorescent quantitative PCR (FQ-PCR) of peripheral
blood mononuclear cells [25], whereas Bonon and co-
workers have reported CMV DNA in 69.5% of WBCs
samples taken from adult and pediatric immunocom-
promised patients using nested PCR assay [27].
In the current study, CMV/EBV co-infection was
found in nine patients (18%), while only one patient
had a single EBV DNA detected in his serum.
Zawilińska and team work have reported infections
with two or three viruses dominated particularly by
CMV and EBV in 65% of adult ALL-HSCT recipi-
ents’ peripheral leukocytes using nested PCR method
[28]. Earlier, Drouct and colleagues had briefly re-
ported signs of CMV and EBV co-infections in graft
recipients and suggested that CMV might encourage
EBV replication and dissemination [29]. Moreover,
Aalto and team work have suggested that CMV may
induce EBV immune reactivation following stimula-
tion of EBV-specific memory B-cells due to iterated
EBV replication [30]. EBV may require another virus
like CMV to increase immunosuppressive status and
mediate a suitable environment for EBV reactivation
as previously reported [30, 31].
Few studies have demonstrated the impact of both
EBV and/or CMV infections on the clinical course of
leukemia disease. Our results revealed that no sig-
nificant association of age and sex with the presence
of EBV and CMV DNA Conversely, Terrazzini and
his colleagues observed that effect of CMV infection
depends on age and sex [32]. In the current study,
the presence of EBV DNA and or CMV DNA in
serum was mostly associated with mucositis and low
Fig. 4 Relation of overall survival with absolute lymphocytic count in pediatric ALL patients
Fig. 5 Relation of overall survival with severe CMV disease (score ≥7) in pediatric ALL patients
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absolute neutrophil count (ANC <1.3 × 109/l) with
borderline significance (p = 0.07). This apparently
may suggest that the suppressive effect of EBV on
some hematological parameters could be attributed
to the presence of CMV DNA infection. However,
we cannot rule out the role of leukemia treatment
but could be a confounder factor that aggravated the
suppressive effect of EBV or CMV. Moreover, the
presence of herpesvirus-6 (HHV6) needs to be evalu-
ated in the pediatric leukemic patients as a reactiva-
tion of HHV6 has been previously reported
following treatment of Tunisian acute leukemia pa-
tients [33]. Furthermore, we have previously reported
that the presence of HHV6 and CMV DNA in
pediatric lymphoma patients using PCR was highly
associated with more frequent episodes of febrile
neutropenia, absolute neutrophil count (<0.8), lym-
phocytes (<0.5) and low hemoglobin level (<9.1)18
amongst pediatric lymphoma patients.
Severe CMV infection and active EBV infection were
significantly associated with worse overall survival of
leukemia patients (p = 0.002 and 0.038, respectively).
EBV/CMV co-infection showed a borderline association
with worse overall survival of patients (p = 0.079). These
findings suggest that severe CMV infection and possibly
EBV infection might play a role in the progression of
leukemia and might be a useful indicator of worsening
the clinical course of the disease. Similar findings were
reported by Yoo and his colleagues on Korean pediatric
umbilical cord blood transplant patients where the pres-
ence of CMV disease was among factors that adversely
affected the survival rates of all patients [34].
Conclusion
CMV and EBV infections are rather common in
pediatric leukemic patients. Qualitative PCR assay is a
hallmark for detection of both EBV and CMV DNA
among leukemic patients. These infections, especially se-
vere CMV infection, were associated with worse overall
survival. Further analysis is still required to evaluate the
role of HHV6 when present with EBV and CMV on wor-
esing the immune status of pediatric leukemic patients.
Acknowledgement
We are indebted to the virology unit, school of medicine in Kuwait for
providing us with ATCC of CMV and EBV. We are also thankful to Wassim
Chehadeh, Associate Professor in the Faculty of Medicine, Kuwait University,
for his critical review of the manuscript.
Funding
The current research is funded by National Cancer Institute, Cairo University.
Availability of data and materials
The datasets used and/or analysed during the current study available from
the corresponding author on reasonable request.
Authors’ contributions
SA put plan and design of the study, supervised and edited manuscript. MAS
supervised the work, edited and revised the manuscript. MF participated in
the design of the study, supervised clinical part, evaluated the results and
participated in editing clinical part of the study. MEW, carried out full clinical
investigations, drafted the data in tables, edited clinical part and participated
in revising the important intellectual contents. ShA, carried out the practical
part, collected clinical and hematological data from patient’s sheets SK
carried out the practical part. NF, carried out practical part and collected
samples, collected clinical and hematological data from patient’s sheets,
drafted the data in tables. MM and AE has performed the statistical analysis
and explicitly reviewed and edited the whole manuscript including tables
and graphs. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The research has been approved by the National Cancer Institute-Cairo
University, IRB. IRB00004025. Organization No. IORG0003381.
Fig. 6 Relation of overall survival with presence of EBV DNA in serum of pediatric ALL patients
Loutfy et al. Virology Journal  (2017) 14:46 Page 10 of 11
Author details
1Virology and Immunology Unit, Cancer Biology Department, National
Cancer Institute, Cairo University, Fom El-Khalig, Cairo 11796, Egypt.
2Microbiology and Immunology Department, Faculty of Pharmacy (Girls), Al
Azhar University, Nasr City, Egypt. 3Pediatric Oncology Department, National
Cancer Institute, Cairo University, Cairo, Egypt. 4Clinical Oncology
Department, Faculty of Medicine, Beni-Suef University, Beni Suef, Egypt.
5Cancer Epidemiology and Biostatistics Department, National Cancer
Institute, Cairo University, Cairo, Egypt. 6Chemistry of natural and microbial
products Department Pharmaceutical Industries Division, National Research
Center, Giza, Egypt. 7Faculty of Medicine, Al Azhar University, Nasr City, Egypt.
8Medical Research Group of Egypt, Cairo, Egypt.
Received: 17 November 2016 Accepted: 23 February 2017
References
1. Cohen J. Eptein-barr virus infection. N Engl J Med. 2000;343:481–92.
2. Loutfy SA, Alam El-Din HM, Ibrahim MF, Hafez MM. Seroprevalence of
herpes simplex virus types 1 and 2, Epstein-Barr virus, and cytomegalovirus
in children with acute lymphoblastic leukemia in Egypt. Saudi Med J.
2006;27:1139–45.
3. Wade JC. Viral infections in patients with hematological malignancies.
Hematology Am Soc Hematol Educ Program. 2006;368–74. doi:10.1182/
asheducation-2006.1.368.
4. Mocarski ES, Shenk T. Cytomegalovirus. In: Knipe DMHP, editor. Fields virol,
vol. 5. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 2701–72.
5. Dolcetti R, Masucci MG. Epstein-Barr virus: Induction and control of cell
transformation. J Cell Physiol. 2003:207–18. doi:10.1002/jcp.10263.
6. Epstein MA, Henle G, Achong BG, Barr YM. Morphological and biological studies
on a virus in cultured lymphoblasts from Burkitt’S lymphoma. J Exp Med
[Internet]. 1965;121:761–70. Available from: http://www.pubmedcentral.nih.gov/
articlerender.fcgi?artid=2138004&tool=pmcentrez&rendertype=abstract.
7. Keegan THM, Glaser SL, Clarke CA, Gulley ML, Craig FE, DiGiuseppe JA, et al.
Epstein-Barr virus as a marker of survival after Hodgkin’s lymphoma: a
population-based study. J Clin Oncol. 2005;23:7604–13.
8. Laytragoon-Lewin N, Chen F, Avila-Cariño J, Zou JZ, Mellstedt H, Ernberg I,
et al. Epstein barr virus (EBV)-carrying cells of a chronic lymphocytic
leukemia (CLL) subpopulation express EBNA1 and LMPS but not EBNA2 in
vivo. Int J Cancer. 1995;63:486–90.
9. Bonon SH, Menoni SM, Rossi CL, De Souza CA, Vigorito AC, Costa DB, et al.
Surveillance of cytomegalovirus infection in haematopoietic stem cell
transplantation patients. J Infect. 2005;50:130–7.
10. Meerbach A, Wutzler P, Häfer R, Zintl F, Gruhn B. Monitoring of Epstein-Barr
virus load after hematopoietic stem cell transplantation for early intervention
in post-transplant lymphoproliferative disease. J Med Virol. 2008;80:441–54.
11. Parasuraman R, Samarapungavan D, Venkat KK. Updated principles and
clinical caveats in the management of infection in renal transplant
recipients. Transplant Rev. 2010;24:43–51.
12. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med.
2007;357:2601–14.
13. Lehtinen M. Maternal Herpesvirus Infections and Risk of Acute
Lymphoblastic Leukemia in the Offspring [Internet]. Am J Epidemiol. 2003.
Available from: http://aje.oupjournals.org/cgi/doi/10.1093/aje/kwg137.
14. Hess RD. Routine Epstein-Barr virus diagnostics from the laboratory
perspective: still challenging after 35 years. J Clin Microbiol. 2004;42(8):3381–7.
15. Pizzo PA, Poplack DG. Principles and practice of pediatric oncology. Wolters
Kluwer Health/Lippincott Williams & Wilkins; 2011.
16. Pui CH, Relling MV, Sandlund JT, Downing JR, Campana D, Evans WE. Rationale
and design of total therapy study XV for newly diagnosed childhood acute
lymphoblastic leukemia. Ann Hematol. 2004;83 Suppl 1:S124–6.
17. Plotkin SA, Starr SE, Friedman HM, Brayman K, Harris S, Jackson S, et al.
Effect of Towne live virus vaccine on cytomegalovirus disease after renal
transplant: A controlled trial. Ann Intern Med. 1991;114:525–31.
18. Van Der Bij W, Torensma R, Van Son WJ, Anema J, Schirm J, Tegzess AM,
et al. Rapid immunodiagnosis of active cytomegalovirus infection by
monoclonal antibody staining of blood leucocytes. J Med Virol.
1988;25:179–88.
19. Loutfy SA, Fawzy M, El-Wakil M, Moneer MM. Presence of human herpes
virus 6 (HHV6) in pediatric lymphomas: impact on clinical course and
association with cytomegalovirus infection. Virol J. 2010;7:287.
20. Mohamed WS, Loutfy SA, Rashed RA, ElAzhary NM, Amer MM. Prospective
study for CMV detection in cancer patients: comparison between PCR,
antigenemia, and serological assays. Life Sci J. 2012;9:4536–41.
21. Hashimoto YE. Investigation of EB VIRUS and cytomegalovirus in rapidly
progressive interstetial pneumonitis in polymyositis/dermatomyositis by in
situ hyberidization and polymerase chain reaction. Clin Immunol immuno
Pathol. 1995;77:298–306.
22. Madi N, Al-Nakib W, Pacsa A. Does cytomegalovirus develop resistance
following antiviral prophylaxis and treatment in renal transplant patients in
Kuwait? Adv Virol. 2011;2011:1–6.
23. Sehgal S, Mujtaba S, Gupta D, Aggarwal R, Marwaha RK. High incidence of
Epstein Barr virus infection in childhood acute lymphocytic leukemia: a
preliminary study. Indian J Pathol Microbiol [Internet]. 2010;53:63–7.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/20090225.
24. Ahmed HG, Osman SI, Ashankyty IM. Incidence of Epstein-Barr virus in pediatric
leukemia in the Sudan. Clin Lymphoma Myeloma Leuk. 2012;12:127–31.
25. Lu Y, Sun LR, Pang XY, Lu ZH, Sui AH. Infection status and clinical
significance of Epstein-Barr virus in pediatric leukemia—a report of 35 cases.
Chin J Cancer. 2007;26:54–7.
26. Debaugnies F, Busson L, Ferster A, Lewalle P, Azzi N, Aoun M, et al.
Detection of Herpesviridae in whole blood by multiplex PCR DNA-based
microarray analysis after hematopoietic stem cell transplantation. J Clin
Microbiol. 2014;52:2552–6.
27. Bonon CSHA, Ross CL, de Souza CA, Vigorito AC, Costa SCB. Comparison of
serology, antigenemia assay and the polymerase chain reaction for
monitoring active cytomegalovirus infections in hematopoietic stem cell
transplantation patients. Virology. 2006;48.
28. Zawilińska B, Kosz-Vnenchak M, Piatkowska-Jakubas B, Kopeć J, Daszkiewicz
E, Skotnicki AB. Herpesviruses mixed infections in allogeneic steam cell
recipients (allo-HSCT). Przegl Epidemiol. 2008;62:39–46.
29. Drouct E, Garnier JL, Chapuis-Cellier C, Touraine JL. Double CMV and EBV
infections are associated with monoclonal immunoglobulins in patients after
renal transplantation. Proc. Sixth Int. Cytomegalovirus Work. Alabama; 1997.
30. Aalto SM, Linnavuori K, Peltola H, Vuori E, Weissbrich B, Schubert J, et al.
Immunoreactivation of Epstein-Barr virus due to cytomegalovirus primary
infection. J Med Virol. 1998;56:186–91.
31. Tselis A. Epstein–Barr Virus and Cytomegalovirus Infections. Viral Infect.
Hum. Nerv. Syst. [Internet]. Basel: Springer Basel; 2013 [cited 2017 Jan 19]. p.
23–46. Available from: http://link.springer.com/10.1007/978-3-0348-0425-7_2
32. Terrazzini N, Bajwa M, Vita S, Cheek E, Thomas D, Seddiki N, et al. A novel
cytomegalovirus-induced regulatory- type T-cell subset increases in size
during older life and links virus-speci fi c immunity to vascular pathology. J
Infect Dis. 2014;209:382–92.
33. Nefzi F, Ben Salem NA, Khelif A, Feki S, Aouni M, Gautheret-Dejean A.
Quantitative analysis of human herpesvirus-6 and human cytomegalovirus
in blood and saliva from patients with acute leukemia. J Med Virol
[Internet]. 2015;87:451–60. [cited 2017 Jan 19] Available from: http://doi.
wiley.com/10.1002/jmv.24059.
34. Yoo KH, Lee SH, Sung KW, Koo HH, Chung NG, Cho B, et al. Current status
of pediatric umbilical cord blood transplantation in Korea: a multicenter
retrospective analysis of 236 cases. Am J Hematol. 2011;86:12–7.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Loutfy et al. Virology Journal  (2017) 14:46 Page 11 of 11
